265 related articles for article (PubMed ID: 21484335)
1. Review of proton pump inhibitors for the initial treatment of heartburn: is there a dose ceiling effect?
Kushner PR; Peura DA
Adv Ther; 2011 May; 28(5):367-88. PubMed ID: 21484335
[TBL] [Abstract][Full Text] [Related]
2. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs?
Bruley des Varannes S; Coron E; Galmiche JP
Best Pract Res Clin Gastroenterol; 2010 Dec; 24(6):905-21. PubMed ID: 21126703
[TBL] [Abstract][Full Text] [Related]
3. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease.
Kahrilas PJ; Howden CW; Hughes N
Am J Gastroenterol; 2011 Aug; 106(8):1419-25; quiz 1426. PubMed ID: 21537361
[TBL] [Abstract][Full Text] [Related]
4. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
Inadomi JM; McIntyre L; Bernard L; Fendrick AM
Am J Gastroenterol; 2003 Sep; 98(9):1940-4. PubMed ID: 14499769
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
Higginbotham TW
Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
[TBL] [Abstract][Full Text] [Related]
6. Lower esophageal sphincter injections for the treatment of gastroesophageal reflux disease.
Watson TJ; Peters JH
Thorac Surg Clin; 2005 Aug; 15(3):405-15. PubMed ID: 16104131
[TBL] [Abstract][Full Text] [Related]
7. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association.
Aanen MC; Weusten BL; Numans ME; de Wit NJ; Samsom M; Smout AJ
J Clin Gastroenterol; 2008; 42(5):441-7. PubMed ID: 18344896
[TBL] [Abstract][Full Text] [Related]
8. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study.
Vakil NB; Huff FJ; Bian A; Jones DS; Stamler D
Am J Gastroenterol; 2011 Aug; 106(8):1427-38. PubMed ID: 21519360
[TBL] [Abstract][Full Text] [Related]
9. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
[TBL] [Abstract][Full Text] [Related]
10. The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease.
Pace F; Pace M
Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):423-7. PubMed ID: 20678016
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn.
Dickman R; Schiff E; Holland A; Wright C; Sarela SR; Han B; Fass R
Aliment Pharmacol Ther; 2007 Nov; 26(10):1333-44. PubMed ID: 17875198
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial: long-term use of proton pump inhibitors in primary care patients - a cross sectional analysis of 901 patients.
Reimer C; Bytzer P
Aliment Pharmacol Ther; 2009 Oct; 30(7):725-32. PubMed ID: 19604180
[TBL] [Abstract][Full Text] [Related]
13. Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies.
Johnson DA; Katz PO
Rev Gastroenterol Disord; 2008; 8(2):98-108. PubMed ID: 18641592
[TBL] [Abstract][Full Text] [Related]
14. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
Abel C; Desilets AR; Willett K
Ann Pharmacother; 2010 May; 44(5):871-7. PubMed ID: 20371754
[TBL] [Abstract][Full Text] [Related]
15. [Proton pump inhibitors according to need. Always for heartburn].
Labenz J
MMW Fortschr Med; 2002 Jun; 144(23):34-7. PubMed ID: 12119901
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
[TBL] [Abstract][Full Text] [Related]
17. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
Gerson LB; Robbins AS; Garber A; Hornberger J; Triadafilopoulos G
Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741
[TBL] [Abstract][Full Text] [Related]
18. Demographic, clinical, and psychological characteristics of the heartburn groups classified using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal reflux disease group.
Lee KJ; Kwon HC; Cheong JY; Cho SW
Digestion; 2009; 79(3):131-6. PubMed ID: 19307735
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of treatment pattern and symptom control in patients with gastroesophageal reflux disease: multihospital questionnaire survey on the current situation in Korea.
Seo SI; Bang CS; Kang HS; Choi MH; Shin WG; Jang HJ; Kim JB; Baik KH; Kae SH; Kim HY
Dis Esophagus; 2017 Oct; 30(10):1-8. PubMed ID: 28859382
[TBL] [Abstract][Full Text] [Related]
20. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
Emerson CR; Marzella N
Clin Ther; 2010 Aug; 32(9):1578-96. PubMed ID: 20974316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
